ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001 ...Middle East

PR Newswire - News
Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data ACM is in partnering...

Hence then, the article about acm biolabs announces positive topline results from a phase i trial of sars cov 2 booster vaccine acm 001 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001 )

Apple Storegoogle play

Last updated :

Also on site :